

PRESS RELEASE

Healthbaby is First Private Cord Blood Bank in Hong Kong to Achieve FACT Accreditation

- Healthbaby is the first private cord blood bank in Hong Kong to receive FACT accreditation.
- Healthbaby is also one of the four cord blood banks in Asia and amongst the seven in the world, to receive FACT and AABB accreditation.
- The FACT accreditation is a major milestone for the cord blood banking industry in Hong Kong as a whole.

Singapore, 16 April 2019 – Cordlife Group Limited (“Cordlife” and together with its subsidiaries, the “Group”), a mainboard listed consumer healthcare company on the Singapore Exchange announced that its Hong Kong subsidiary Healthbaby Biotech (Hong Kong) Co. Limited (“Healthbaby”), has become the first private cord blood bank in Hong Kong to attain accreditation from Foundation for the Accreditation of Cellular Therapy (“FACT”). With this new accreditation, Healthbaby becomes one of the four cord blood banks in Asia and amongst the seven in the world, to receive FACT and AABB accreditation.

The accreditation was awarded after the FACT Cord Blood Accreditation Committee and FACT-Netcord Board of Directors determined that Healthbaby has met or exceeded all FACT standards, following a detailed peer-reviewed on-site inspection. The on-site assessment was carried out by a team of expert inspectors who are qualified by training and have been performing cellular therapy functions in their daily practice.

FACT is the only accrediting agency that focuses on all quality aspects of cord blood collection, processing, testing, banking, selection and release. Founded in 1996, FACT establishes standards for high quality medical and laboratory practice in cellular therapies. Physicians and patients are more confident when cord blood units come from FACT accredited cord blood banks because they have been independently assessed and their practices have met specific standards to ensure patient safety.

“We are pleased that Healthbaby has received FACT accreditation. This is a significant milestone for the Group as it is our second facility to achieve accreditation from FACT and AABB,” said Ms Tan Poh Lan, Cordlife’s Group Chief Executive Officer. She added, “With this

achievement, along with the completion of our consolidation in Hong Kong, we believe our Group is poised to achieve higher growth as the market leader in Hong Kong.”

“Achieving FACT accreditation is a major milestone not only for Healthbaby but also for the cord blood banking industry in Hong Kong as a whole. As the leading cord blood bank in Hong Kong, we have continuously evolved our processes since our inception in 2006. Our latest accreditation proved that we are well-positioned to spearhead future developments within the industry in the country,” said Ms Circle Yuen, the Group’s Hong Kong Chief Executive Officer.

– End –

About Healthbaby Hong Kong

Founded in 2006, Healthbaby Biotech (Hong Kong) Co. Limited (“Healthbaby” or the “Company”), the leading cord blood bank in Hong Kong, was acquired by Cordlife Group Limited in January 2018. The Company also has a sales office in Macau since 2007. Healthbaby is the only cord blood bank in Hong Kong to offer fully automated cord blood storage system - BioArchive® system, which is adopted by most of public cord blood banks in the world. Quality wise, Healthbaby has been accredited by The Hong Kong Laboratory Accreditation Scheme (HOKLAS) since 2007, by AABB (formerly known as the American Association of Blood Banks) since 2009 and The College of American Pathologists (CAP) since 2012. The Company is also the first private cord blood bank in Hong Kong to achieve FACT accreditation, making them one of the four cord blood banks in Asia and among the seven in the world, to achieve accreditation from FACT and AABB. Other services offered by Healthbaby include umbilical cord banking and newborn metabolic screening. For more information, visit www.healthbaby.hk.

About Cordlife Group Limited

Incorporated in 2001, Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”) is a consumer healthcare group and one of the key providers of cord blood as well as cord lining banking services in Asia. Cordlife has been listed on the mainboard of Singapore Exchange (SGX: P8A) since March 2012.

Cordlife owns an extensive network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks; and is amongst the top three market leaders in India and

Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank in the country, Healthbaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife holds indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife also expanded its presence in Myanmar and Vietnam to provide cord blood and cord lining banking services.

Beyond cord blood and cord lining/tissue banking, Cordlife offers a comprehensive suite of diagnostics services for the family including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.

Quality and customer focus are amongst some of the cornerstones of Cordlife. The Group's stem cell processing and storage facilities in Singapore, Hong Kong, India, the Philippines and Malaysia are accredited by AABB, the organisation behind the world's gold standard for cord blood banking. In addition, Cordlife Singapore and Healthbaby are accredited by FACT, another world-class accreditation body for cord blood banks globally. This makes Cordlife Singapore and Healthbaby, two of just four cord blood banks in Asia, and seven in the world, to be accredited by both AABB and FACT concurrently. In the area of clinical diagnostics, Cordlife India, Healthbaby and Hong Kong Screening Centre are accredited by the College of American Pathologists ("CAP"). These quality achievements underpin the Group's commitment to providing reliable healthcare solutions to have a better quality of life through innovation and technological advancement.

For more information, visit <http://cordlife.listedcompany.com>.

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : **Financial PR Pte Ltd**
4 Robinson Road #04-01,
The House of Eden, Singapore 048543

CONTACT : Mr Ngo Yit Sung / Ms Yong Jing Wen

OFFICE : (65) 6438 2990

EMAIL : yitsung@financialpr.com, sg / jingwen@financialpr.com, sg
